8-K: Alphatec Holdings Completes Repurchase of 2026 Convertible Notes and Updates Share Cap for 2030 Notes

Alphatec Holdings finalized the repurchase of $253.0 million of its 2026 convertible notes and updated the share cap related to the 2030 convertible notes.

Summary

• Alphatec Holdings, Inc. issued $405 million in principal amount of 0.75% Convertible Senior Notes due 2030 on March 7, 2025.
• The company will settle conversions of these notes with cash, shares, or a combination, at its discretion.
• Until the company increases its authorized shares or makes other shares available, conversions will be settled with a combination of cash and shares, capped at 29,700,000 shares.
• On March 10, 2025, Alphatec completed the repurchase of $253.0 million of its 0.75% convertible senior notes due 2026.
• Shares previously reserved for the 2026 notes are now available for the 2030 notes.
• The share cap for the 2030 notes includes 211,054 shares related to the repurchases settled on March 10, 2025.

Sentiment

Score: 7

Explanation: The announcement is neutral to positive, reflecting proactive debt management and financial planning. The repurchase of notes is generally viewed favorably, but the share cap introduces a potential constraint.

Positives

• The repurchase of the 2026 notes reduces Alphatec's near-term debt obligations.
• The availability of shares previously reserved for the 2026 notes provides flexibility in settling conversions of the 2030 notes.

Negatives

• The company is currently limited in its ability to settle conversions of the 2030 notes entirely with shares due to the share cap.
• The company will be required to settle conversions in a combination of cash and shares, subject to a cap on the total number of shares deliverable upon conversion.

Risks

• The company may need to increase its authorized shares to fully settle conversions of the 2030 notes with shares.
• The need to settle conversions with a combination of cash and shares could impact the company's cash flow and potentially dilute existing shareholders.

Future Outlook

The company will need to increase its authorized shares or make other shares available to fully settle conversions of the 2030 notes with shares. The company will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the company's election.

Industry Context

Convertible note offerings and repurchases are common financial strategies in the medical device industry, allowing companies like Alphatec to manage their capital structure and raise funds for growth initiatives. The management of convertible notes is a key aspect of financial planning for companies in this sector.

Comparison to Industry Standards

• Other medical device companies, such as NuVasive and Globus Medical, have also utilized convertible notes to raise capital.
• The interest rate of 0.75% on the 2030 notes is relatively low, reflecting the current interest rate environment and Alphatec's creditworthiness.
• The repurchase of the 2026 notes is a common strategy to reduce debt and manage future dilution.

Stakeholder Impact

• Shareholders may experience dilution if the company settles conversions of the 2030 notes with shares.
• The repurchase of the 2026 notes reduces the company's debt burden, potentially benefiting creditors.

Next Steps

• The company will need to monitor the conversion activity of the 2030 notes.
• Alphatec may need to seek shareholder approval to increase its authorized shares.

Key Dates